PMID- 31765999
OWN - NLM
STAT- MEDLINE
DCOM- 20210119
LR  - 20210119
IS  - 2211-0356 (Electronic)
IS  - 2211-0348 (Linking)
VI  - 38
DP  - 2020 Feb
TI  - Growing evidence supporting the use of mesenchymal stem cell therapies in 
      multiple sclerosis: A systematic review.
PG  - 101860
LID - S2211-0348(19)30849-1 [pii]
LID - 10.1016/j.msard.2019.101860 [doi]
AB  - BACKGROUND: Multiple sclerosis (MS) typically arises in early/middle adulthood 
      and is characterized by a progressive disability of the central nervous system 
      (CNS). Currently approved therapies do not promote tissue repair or stop disease 
      progression. Emerging data demonstrate that stem cells present a great potential 
      in regenerative medicine and, consequently, have also been widely investigated as 
      a potential treatment for MS. Therefore, the aim of this study was to conduct a 
      systematic review to inquire into the safety, tolerability, and efficacy of 
      mesenchymal stem cells (MSCs) therapies in MS. METHODS: Three electronic 
      databases (Web of Science, PubMed, and Cochrane) were searched from April until 
      June 2019. Clinical trials or case reports with information related to the 
      effects of MSC therapies in MS patients were considered for this review. RESULTS: 
      10 manuscripts were selected, namely 7 uncontrolled clinical trials, 2 randomized 
      controlled clinical trials, and 1 case report. The overall quality of the studies 
      was considered good. Besides minor adverse events (AEs), it was reported one case 
      of encephalopathy with seizures and two cases of iatrogenic meningitis, which 
      were not related to the treatment, but with the administration route. The 
      analyses of the expanded disability status scale (EDSS) in the uncontrolled 
      clinical trials demonstrated that 48 patients improved, 39 maintained and 16 
      worsened their clinical condition. Regarding the randomized studies, one did not 
      show statistically significant variations in the mean EDSS score and in the other 
      the mean EDSS score was statistically significantly lower for the experimental 
      group. The case report also showed an improvement in the EDSS score. CONCLUSIONS: 
      MSCs transplantation proved to be a safe and tolerable therapy. Their potential 
      therapeutic benefits were also validated. However, larger placebo controlled 
      blinded clinical trials will be required to establish the long term safety and 
      efficacy profile of these therapies for MS. Their translation into the clinical 
      practice can provide a new hope for the patients of this highly debilitating 
      disease.
CI  - Copyright (c) 2019 Elsevier B.V. All rights reserved.
FAU - Oliveira, Ana Gabriela
AU  - Oliveira AG
AD  - Medicine School, University of Minho, Campus de Gualtar, Braga 4710-057, 
      Portugal.
FAU - Goncalves, Margarida
AU  - Goncalves M
AD  - Medicine School, University of Minho, Campus de Gualtar, Braga 4710-057, 
      Portugal.
FAU - Ferreira, Helena
AU  - Ferreira H
AD  - 3B's Research Group, I3B's - Research Institute on Biomaterials, Biodegradables 
      and Biomimetics, University of Minho, Headquarters of the European Institute of 
      Excellence on Tissue Engineering and Regenerative Medicine, Avepark, Parque de 
      Ciencia e Tecnologia, Zona Industrial da Gandra, Barco, Guimaraes 4805-017, 
      Portugal; ICVS/3B's - PT Government Associate Laboratory, Braga, Guimaraes, 
      Portugal. Electronic address: helenaferreira@i3bs.uminho.pt.
FAU - M Neves, Nuno
AU  - M Neves N
AD  - 3B's Research Group, I3B's - Research Institute on Biomaterials, Biodegradables 
      and Biomimetics, University of Minho, Headquarters of the European Institute of 
      Excellence on Tissue Engineering and Regenerative Medicine, Avepark, Parque de 
      Ciencia e Tecnologia, Zona Industrial da Gandra, Barco, Guimaraes 4805-017, 
      Portugal; ICVS/3B's - PT Government Associate Laboratory, Braga, Guimaraes, 
      Portugal; The Discoveries Centre for Regenerative and Precision Medicine, 
      Headquarters at University of Minho, Avepark, Barco, Guimaraes 4805-017, 
      Portugal. Electronic address: nuno@i3bs.uminho.pt.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20191118
PL  - Netherlands
TA  - Mult Scler Relat Disord
JT  - Multiple sclerosis and related disorders
JID - 101580247
SB  - IM
MH  - Humans
MH  - *Mesenchymal Stem Cell Transplantation/adverse effects
MH  - Multiple Sclerosis/*therapy
MH  - *Outcome Assessment, Health Care
OTO - NOTNLM
OT  - Adverse events
OT  - Expanded disability status scale
OT  - Mesenchymal stem cells
OT  - Multiple sclerosis
OT  - Therapeutic efficacy
COIS- Declaration of Competing Interests The authors declare no conflicts of interest 
      pertinent to this study.
EDAT- 2019/11/26 06:00
MHDA- 2021/01/20 06:00
CRDT- 2019/11/26 06:00
PHST- 2019/08/06 00:00 [received]
PHST- 2019/10/29 00:00 [revised]
PHST- 2019/11/16 00:00 [accepted]
PHST- 2019/11/26 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
PHST- 2019/11/26 06:00 [entrez]
AID - S2211-0348(19)30849-1 [pii]
AID - 10.1016/j.msard.2019.101860 [doi]
PST - ppublish
SO  - Mult Scler Relat Disord. 2020 Feb;38:101860. doi: 10.1016/j.msard.2019.101860. 
      Epub 2019 Nov 18.